Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
$9.68
$0.61
$24.20
$820K1.4119,299 shs416,900 shs
Allena Pharmaceuticals, Inc. stock logo
ALNA
Allena Pharmaceuticals
$0.07
$0.06
$1.17
$37K1.1315.69 million shs96,558 shs
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
$0.86
$2.21
$37.35
$6.75M0.02206,730 shs31,300 shs
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
$0.77
$0.77
$0.67
$3.77
$3.37M1.12N/AN/A
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
$2.64
+5.6%
$2.55
$0.82
$3.38
$96.04M1.131.78 million shs1.27 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
0.00%0.00%0.00%0.00%0.00%
Allena Pharmaceuticals, Inc. stock logo
ALNA
Allena Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
0.00%0.00%0.00%0.00%0.00%
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.00%0.00%0.00%0.00%-39.76%
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
+0.81%0.00%+0.40%+39.66%+131.48%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Allena Pharmaceuticals, Inc. stock logo
ALNA
Allena Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
N/AN/AN/AN/AN/AN/AN/AN/A
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
2.0664 of 5 stars
3.52.00.00.02.60.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
0.00
N/AN/AN/A
Allena Pharmaceuticals, Inc. stock logo
ALNA
Allena Pharmaceuticals
0.00
N/AN/AN/A
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
0.00
N/AN/AN/A
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.00
N/AN/AN/A
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
3.00
Buy$9.00240.91% Upside

Current Analyst Ratings Breakdown

Latest ACOR, GENE, MBOT, ALNA, and BBI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2025
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
$117.63M0.00N/A0.02($127.17) per share0.00
Allena Pharmaceuticals, Inc. stock logo
ALNA
Allena Pharmaceuticals
N/AN/AN/AN/A$0.23 per shareN/A
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
$4.64M0.00N/AN/A$9.75 per share0.00
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
$7.66M0.44N/AN/A$0.25 per share3.06
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
N/AN/AN/AN/A$0.17 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
-$252.85M-$203.83N/AN/AN/A-214.95%-2,206.93%-83.28%N/A
Allena Pharmaceuticals, Inc. stock logo
ALNA
Allena Pharmaceuticals
-$48.66MN/A0.00N/AN/AN/A-287.46%-146.58%N/A
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
-$39.47M-$13.52N/AN/AN/A-643.48%-156.10%-128.23%N/A
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
-$7.88MN/A0.00N/AN/AN/AN/A7/28/2025 (Estimated)
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
-$11.44M-$0.65N/AN/AN/AN/A-110.27%-94.20%8/13/2025 (Estimated)

Latest ACOR, GENE, MBOT, ALNA, and BBI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q1 2025
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
-$0.15-$0.08+$0.07-$0.08N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
N/AN/AN/AN/AN/A
Allena Pharmaceuticals, Inc. stock logo
ALNA
Allena Pharmaceuticals
N/AN/AN/AN/AN/A
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
N/AN/AN/AN/AN/A
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
N/AN/AN/AN/AN/A
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
3.07
0.33
0.26
Allena Pharmaceuticals, Inc. stock logo
ALNA
Allena Pharmaceuticals
N/A
1.58
1.58
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
N/A
6.36
6.36
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.01
0.88
0.83
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
N/A
16.19
16.19
CompanyEmployeesShares OutstandingFree FloatOptionable
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
1111.24 million1.21 millionNo Data
Allena Pharmaceuticals, Inc. stock logo
ALNA
Allena Pharmaceuticals
35122.08 million117.57 millionNot Optionable
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
162.87 million2.74 millionNot Optionable
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
504.41 million4.53 millionOptionable
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
2036.38 million34.65 millionOptionable

Recent News About These Companies

Traders Buy High Volume of Microbot Medical Call Options (NASDAQ:MBOT)
MBOT - Microbot Medical Inc News - Morningstar
MBOT Microbot Medical Inc. - Seeking Alpha
Microbot Medical Joins Russell Microcap Index
Microbot Medical Inc. (MBOT) - Yahoo Finance
Brokers Issue Forecasts for MBOT Q1 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Acorda Therapeutics stock logo

Acorda Therapeutics NASDAQ:ACOR

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.

Allena Pharmaceuticals stock logo

Allena Pharmaceuticals NASDAQ:ALNA

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

Brickell Biotech stock logo

Brickell Biotech NASDAQ:BBI

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Genetic Technologies stock logo

Genetic Technologies NASDAQ:GENE

$0.76 0.00 (0.00%)
As of 05/20/2025

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Microbot Medical stock logo

Microbot Medical NASDAQ:MBOT

$2.64 +0.14 (+5.60%)
Closing price 04:00 PM Eastern
Extended Trading
$2.62 -0.02 (-0.57%)
As of 05:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.